Carfilzomib for Injection 30mg
CARFLIEVA 30MG (Carfilzomib for Injection 30mg) is a specialized anticancer medicine used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It contains Carfilzomib, a highly effective proteasome inhibitor that helps slow down and control the growth of cancer cells in the body. This oncology injection is commonly prescribed by healthcare professionals as part of advanced chemotherapy and targeted cancer treatment protocols.
Multiple myeloma develops when abnormal plasma cells multiply uncontrollably inside the bone marrow. These cancerous cells interfere with the normal production of blood cells and can weaken bones, reduce immunity, and affect kidney function. CARFLIEVA 30MG works by targeting and blocking proteasomes, which are responsible for breaking down proteins inside cancer cells. When proteasomes are inhibited, cancer cells accumulate damaged proteins and eventually die, helping reduce the spread of the disease.
CARFLIEVA 30MG is widely used in modern oncology treatment because of its effectiveness in managing relapsed or refractory multiple myeloma. It is often prescribed for patients who have previously received other cancer therapies but require further treatment support due to disease progression or recurrence. Doctors may use this medicine alone or in combination with other anticancer medicines depending on the patient’s condition and treatment plan.
This Carfilzomib injection is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable clinical performance. The medicine is intended for hospital and oncology center use and should only be administered by trained healthcare professionals under proper medical supervision.
Patients receiving CARFLIEVA 30MG usually undergo regular medical monitoring, blood tests, and health assessments during treatment to help improve treatment outcomes and reduce the risk of complications. Oncology specialists carefully determine the dosage and treatment schedule based on the patient’s overall health, response to therapy, and stage of cancer.
Due to its advanced mechanism of action and targeted cancer therapy approach, CARFLIEVA 30MG has become an important medicine in the management of multiple myeloma and modern hematology-oncology treatment protocols.
View Details
Ibrutinib Capsules 140mg
IBRULIEVA 140 MG (Ibrutinib Capsules 140 mg) is a targeted anticancer medicine used in the treatment of certain blood cancers and lymphatic system cancers. It contains Ibrutinib, a highly effective Bruton's Tyrosine Kinase (BTK) inhibitor that helps slow down and control the growth of abnormal cancer cells in the body. This medicine is commonly prescribed by oncologists and hematology specialists for the management of chronic blood-related malignancies and advanced lymphoma conditions.
Ibrutinib works by targeting specific proteins responsible for the growth and survival of cancer cells. By blocking BTK activity, the medicine interferes with cancer cell signaling pathways and helps reduce the spread of abnormal B-cells. Due to its targeted mechanism of action, IBRULIEVA 140 MG has become an important medicine in modern hematology-oncology treatment protocols.
This targeted therapy capsule is widely used in the treatment of:
• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)
• Mantle Cell Lymphoma (MCL)
• Waldenström Macroglobulinemia (WM)
• Marginal Zone Lymphoma (MZL)
• Chronic Graft Versus Host Disease (cGVHD)
Doctors may prescribe IBRULIEVA alone or in combination with other oncology medicines depending on the patient’s medical condition, stage of cancer, treatment history, and response to therapy.
IBRULIEVA 140 MG is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable therapeutic performance. The medicine is intended strictly for medical use and should only be taken under the supervision of qualified healthcare professionals.
Blood cancers and lymphatic malignancies can affect the immune system, bone marrow, lymph nodes, and overall health. Targeted cancer therapies like Ibrutinib help improve disease management by specifically targeting cancer-related pathways without affecting healthy cells as extensively as traditional chemotherapy.
Patients receiving IBRULIEVA 140 MG may require regular blood tests, medical monitoring, and health assessments during treatment to help manage side effects and improve treatment outcomes. Doctors carefully determine dosage and treatment duration based on the patient’s overall condition and treatment goals.
Due to its effectiveness in targeted cancer treatment and hematology care, IBRULIEVA 140 MG is widely used in hospitals, oncology centers, hematology clinics, and advanced cancer treatment programs.
View Details
Melphalan Tablet IP 2mg
MELIEVA 2 MG (Melphalan Tablet IP 2 mg) is an anticancer chemotherapy medicine used in the treatment and management of multiple myeloma, ovarian cancer, and certain other cancer-related conditions. It contains Melphalan, a well-known alkylating agent that helps destroy cancer cells by interfering with their DNA and preventing them from multiplying inside the body.
Melphalan is widely used in oncology and hematology treatment programs because of its effectiveness in slowing the growth and spread of abnormal cancer cells. This medicine is commonly prescribed by oncologists as part of chemotherapy treatment protocols for patients requiring long-term cancer management and supportive oncology care.
Cancer cells grow and divide rapidly, affecting normal body functions and overall health. MELIEVA 2 MG works by damaging the genetic material of cancer cells, which reduces their ability to survive and reproduce. This targeted effect helps control cancer progression and supports modern chemotherapy treatment strategies.
MELIEVA 2 MG is mainly used in:
• Multiple myeloma treatment
• Ovarian cancer management
• Bone marrow-related cancer conditions
• Advanced oncology treatment programs
• Certain hematological disorders under specialist supervision
This anticancer medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable therapeutic performance. The medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology treatment.
Doctors may prescribe MELIEVA alone or in combination with other chemotherapy medicines depending on the patient’s medical condition, cancer type, stage of disease, and response to therapy.
Patients receiving Melphalan therapy may require regular blood tests, bone marrow monitoring, liver function assessments, and medical evaluations during treatment. Chemotherapy medicines can affect healthy cells along with cancer cells, so close medical supervision is important for improving treatment outcomes and reducing complications.
Due to its effectiveness in oncology and hematology care, MELIEVA 2 MG has become an important medicine in cancer treatment protocols and long-term chemotherapy management programs.
View Details
Acalabrutinib Capsules 100mg
ACALIEVA 100MG (Acalabrutinib Capsules 100mg) is a targeted anticancer medicine used in the treatment of certain blood cancers and lymphatic system cancers. It contains Acalabrutinib, a highly effective Bruton's Tyrosine Kinase (BTK) inhibitor that helps slow down the growth and spread of abnormal cancer cells in the body. This medicine is commonly prescribed by oncologists and hematology specialists as part of advanced cancer treatment protocols for chronic blood-related malignancies.
Acalabrutinib works by blocking the activity of BTK proteins that are involved in the growth and survival of cancerous B-cells. By interrupting these cancer cell signaling pathways, ACALIEVA 100MG helps reduce the multiplication and survival of abnormal cells, supporting long-term cancer management and disease control.
This targeted therapy medicine is widely used in modern hematology-oncology treatment because of its precision-based mechanism and effectiveness in managing blood cancers with fewer effects on healthy cells compared to some traditional chemotherapy medicines.
ACALIEVA 100MG is mainly prescribed for the treatment of:
• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)
• Mantle Cell Lymphoma (MCL)
• Certain relapsed or refractory blood cancers
• Advanced hematology-oncology treatment programs
Doctors may prescribe Acalabrutinib Capsules alone or in combination with other anticancer medicines depending on the patient’s condition, stage of disease, previous treatment history, and response to therapy.
Blood cancers can affect the immune system, bone marrow, lymph nodes, and overall health. Targeted therapy medicines like Acalabrutinib help control cancer progression by specifically targeting cancer-related proteins responsible for abnormal B-cell growth.
ACALIEVA 100MG is manufactured under strict pharmaceutical quality standards to ensure safety, purity, and reliable therapeutic performance. The medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and hematology treatment.
Patients undergoing treatment with ACALIEVA may require regular blood tests, medical monitoring, infection screening, and overall health assessments during therapy. Proper monitoring helps improve treatment effectiveness and reduce the risk of complications or serious side effects.
Due to its effectiveness in targeted cancer therapy and hematology care, ACALIEVA 100MG has become an important medicine in modern oncology treatment protocols and long-term blood cancer management programs.
View Details
Hydroxyurea Capsules IP 500mg
HYDLIEVA 500MG (Hydroxyurea Capsules IP 500mg) is a prescription medicine used in the treatment of certain blood disorders and cancers. It contains Hydroxyurea 500mg, a well-established antimetabolite medication that works by slowing the growth and multiplication of abnormal cells in the body. Hydroxyurea is widely prescribed by hematologists and oncologists for managing conditions such as chronic myeloid leukemia, sickle cell disease, and other myeloproliferative disorders.
HYDLIEVA 500MG plays an important role in modern hematology and oncology treatment because it helps control excessive blood cell production and reduces disease-related complications. The medicine works by interfering with DNA synthesis, which slows down the growth of rapidly dividing cells. This mechanism makes Hydroxyurea effective in managing both cancerous and non-cancerous blood disorders.
Patients with blood-related conditions often require long-term treatment and careful monitoring. HYDLIEVA 500MG helps improve disease control, reduce complications, and support overall quality of life when used under appropriate medical supervision.
This medicine is commonly prescribed for:
• Chronic Myeloid Leukemia (CML)
• Sickle Cell Disease
• Polycythemia Vera
• Essential Thrombocythemia
• Certain Myeloproliferative Disorders
• Blood Cell Production Disorders
• Hematology and Oncology Treatment Programs
Hydroxyurea has been widely used for many years and remains an important treatment option in specialized blood disorder management. It is particularly valuable in sickle cell disease, where it helps reduce painful crises and improve overall disease outcomes.
HYDLIEVA 500MG is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. The medicine should only be used under the supervision of qualified healthcare professionals.
Patients receiving Hydroxyurea therapy may require regular blood tests, kidney function monitoring, liver function assessments, and medical evaluations throughout treatment. These assessments help ensure treatment effectiveness and identify potential side effects early.
Due to its proven effectiveness in hematology and oncology care, HYDLIEVA 500MG remains an important medicine in modern blood disorder treatment programs.
View Details
Imatinib Mesylate Tablets IP 400mg
IMALIEVA 400 MG (Imatinib Mesylate Tablets IP 400 mg) is a targeted anticancer medicine used for the treatment of certain blood cancers, gastrointestinal tumors, and other cancers driven by specific genetic abnormalities. It contains Imatinib Mesylate 400 mg, a tyrosine kinase inhibitor (TKI) that works by blocking abnormal proteins responsible for the growth and multiplication of cancer cells.
Imatinib revolutionized cancer treatment by becoming one of the first successful targeted therapies. Unlike conventional chemotherapy, which affects both healthy and cancerous cells, Imatinib specifically targets abnormal enzymes that contribute to cancer progression. This targeted approach helps slow disease progression, improve treatment outcomes, and support long-term cancer management.
IMALIEVA 400 MG is widely prescribed by oncologists and hematologists for patients diagnosed with specific cancers that contain abnormal tyrosine kinase activity. By targeting these cancer-driving proteins, the medicine helps control tumor growth and reduce the spread of disease.
This medicine is commonly used in the treatment of:
• Chronic Myeloid Leukemia (CML)
• Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
• Gastrointestinal Stromal Tumors (GIST)
• Myelodysplastic/Myeloproliferative Disorders (MDS/MPD)
• Hypereosinophilic Syndrome (HES)
• Dermatofibrosarcoma Protuberans (DFSP)
• Advanced Hematological and Solid Tumor Conditions
IMALIEVA 400 MG may be prescribed as a first-line treatment or as part of long-term cancer management programs depending on the patient's diagnosis, treatment history, and response to therapy.
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and hematology care.
Patients receiving Imatinib therapy may require regular blood tests, liver function monitoring, kidney assessments, and periodic medical evaluations to ensure optimal treatment outcomes and early detection of potential side effects.
Due to its proven effectiveness in targeted cancer therapy, IMALIEVA 400 MG has become one of the most important medicines in modern oncology and hematology treatment programs worldwide.
View Details
Azacitidine for Injection 100MG
AZALIEVA 100 mg contains Azacitidine, a hypomethylating agent and pyrimidine nucleoside analogue. It incorporates into DNA and RNA, leading to inhibition of DNA methyltransferase, reactivation of tumor suppressor genes, and normalization of bone marrow function. It is mainly used in myelodysplastic syndromes (MDS).
View Details
Plerixafor Injection 24mg
MOZOLIEVA 24 mg contains Plerixafor, a hematopoietic stem cell mobilizer. It is a CXCR4 chemokine receptor antagonist that disrupts the interaction between CXCR4 and SDF-1α, causing rapid release of CD34+ stem cells from the bone marrow into peripheral blood for collection.
View Details
Fludarabine Phosphate for Injection 50mg
FLULIEVA 50 mg contains Fludarabine Phosphate, a purine nucleoside analogue antimetabolite. It is intracellularly converted to fludarabine triphosphate, which inhibits DNA polymerase, ribonucleotide reductase, and DNA primase, leading to suppression of DNA synthesis and apoptosis. It is widely used in hematologic malignancies.
View Details
Methotrexate Injection 500mg
TREXLIEVA 500 mg contains Methotrexate, an antimetabolite and antifolate chemotherapeutic agent. It inhibits dihydrofolate reductase (DHFR), blocking folate metabolism and DNA synthesis in rapidly dividing cells. This strength is commonly used in high-dose methotrexate (HD-MTX) oncology protocols.
View Details
Methotrexate Injection IP 50mg
TREXLIEVA 50 mg contains Methotrexate, an antimetabolite and antifolate chemotherapeutic agent. It inhibits dihydrofolate reductase (DHFR), leading to reduced DNA synthesis and cell replication, particularly in rapidly dividing cells. It is widely used in oncology, autoimmune diseases, and medical oncology protocols.
View Details
Bortezomib Injection IP 3.5mg
BORTLIEVA contains Bortezomib, a proteasome inhibitor used in cancer treatment. It works by blocking proteasomes in cells, leading to accumulation of proteins and apoptosis (cell death) of cancer cells.
View Details
